Friday, May 9, 2025 5/9/2025

Discovery of novel surface biomarkers of latently HIV-infected cells using lamprey antibody technology

Award Number: R01AI117818
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Discovery of novel surface biomarkers of latently HIV-infected cells using lamprey antibody technology - ¿ DESCRIPTION (provided by applicant): PROJECT SUMMARY It is clear that latently infected CD4+ T cells in HAART treated HIV-infected individuals are the major reservoir and obstacle to eradication. This research proposal specifically intends to address the FOA entitled "Targeting Latently infected cells without reactivation" with the following specific objective proposed by the FOA: "to identify novel biomarkers of latently-infected cells that could be used to selectively target and kill cells harboring latent HIV-DNA". Current work has attempted to identify cell surface markers that preferentially harbor latent HIV, that is replication competent upon activation, however, these markers are not necessarily HIV-specific, at best can enrich for about 60% of the total HIV reservoir in CD4+ T cells, and often represent a substantial percentage of the total memory CD4+ T cell population, which would make targeted elimination of these cells as a therapy problematic. To circumvent this problem, we propose an unbiased approach where we will employ the non-conventional variable lymphocyte receptor (VLR) antibody platform of the evolutionary distant sea lamprey to isolate novel VLR antibodies that specifically target HIV-infected cells. We hypothesize that the large evolutionary distance of jawless vertebrates and the different protein architecture of VLR antibodies allows these proteins to detect antigens expressed by latently infected cells that conventional monoclonal antibodies cannot readily bind for structural or tolerogenic reasons. Optimism for success stems from our extensive experience in the generation of novel monoclonal VLR antibodies in lampreys that identify novel surface receptors of immune cell subsets that previously were not identified using standard methodologies. In Aim 1 we propose to use an in vitro model of HIV latency in primary CD4+ T cells to immunize lamprey larvae and then screen for monoclonal VLRs that can specifically bind to latently infected cells in vitro, using a high throughput assay system. In aim 2 we will tet a number of `candidate' VLRs that will be tested for their abilities to bind to and specifically deplete HIV-infected cells from ex vivo blood samples from HIV-infected individuals off and on HAART. In aim 2 we will test VLRs from a cohort of HIV-infected individuals who have been treated for variable duration to assess the generalizability of the VLRs ability to bind to latent cells. In aim 3, we will then characterize the protein or glycoprotein epitopes that are being recognized by VLRs using mass spectroscopy and biochemical methods. The current proposal has the potential to discover novel surface markers that can then be exploited to produce monoclonal agents that can more specifically target latently infected cells in vivo.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2017	GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO	27 KING'S COLLEGE CIR	TORONTO	ON			CAN	Allergy and Infectious Diseases Research	000	3	9/23/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = -$2,414 )
2019	2017	GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO	27 KING'S COLLEGE CIR	TORONTO	ON	M5S 1A1		CAN	Allergy and Infectious Diseases Research	000	3	7/24/2019	NON-COMPETING CONTINUATION	-$2,414
														Subtotal = -$2,414

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2017	GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO	27 KING'S COLLEGE CIR	TORONTO	ON	M5S 1A1		CAN	Allergy and Infectious Diseases Research	000	3	3/7/2018	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $209,008 )
2017	2017	UNIVERSITY OF TORONTO	27 KING'S COLLEGE CIR	TORONTO	ON	M5S 1A1		CAN	Allergy and Infectious Diseases Research	000	3	2/27/2017	NON-COMPETING CONTINUATION	$209,008
														Subtotal = $209,008

Issue Date FY: 2016 ( Subtotal = $219,025 )
2016	2016	UNIVERSITY OF TORONTO	27 KING'S COLLEGE CIRCLE	TORONTO				CAN	Allergy and Infectious Diseases Research	001	2	2/23/2016	NON-COMPETING CONTINUATION	$219,025
2016	2015	UNIVERSITY OF TORONTO	27 KING'S COLLEGE CIRCLE	TORONTO		M5S 1A1		CAN	Allergy and Infectious Diseases Research	000	1	1/21/2016	NEW	$0
														Subtotal = $219,025

Issue Date FY: 2015 ( Subtotal = $219,025 )
2015	2015	UNIVERSITY OF TORONTO	27 KING'S COLLEGE CIRCLE	TORONTO				CAN	Allergy and Infectious Diseases Research	000	1	2/12/2015	NEW	$219,025
														Subtotal = $219,025

Grand Total All Awards = $644,644

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Discovery of novel surface biomarkers of latently HIV-infected cells using lamprey antibody technology

Award Number: R01AI117818

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer